EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieÄquivalenzstudieMultizentrische Studie

Low‐dose pegylated recombinant human granulocyte‐colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open‐label, randomized, non‐inferiority trial

Sheng Yang, Shan-Shan Chen, Chang-Gong Zhang, Ying-Lei Zhou, Meng Xiu, Pin Zhang iD

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16151 ↗

At a glance

Randomisierte kontrollierte Studie in British Journal of Clinical Pharmacology, 2024. Written by Sheng Yang and 5 co-authors. Institution: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Major MEDLINE topics: Breast Neoplasms, Polyethylene Glycols, Granulocyte Colony-Stimulating Factor, Neutropenia. Cited 2 times so far (Crossref); 34 references. Funded by: CAMS Innovation Fund for Medical Sciences (CIFMS), National Natural Science Foundation Fund of China, National Outstanding Youth Science Fund Project of National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

The recommended dosage of pegylated recombinant human granulocyte‐colony stimulating factor (PEG‐rhG‐CSF) for Western chemotherapy patients is 6 mg per cycle. However, for Eastern Asians, the optimal dose remains unknown.

Methods

This open‐label, randomized, non‐inferiority trial (NCT05283616) enrolled Chinese female breast cancer patients receiving adjuvant chemotherapy. Participants were randomized to receive either 3 or 6 mg of PEG‐rhG‐CSF per cycle, stratified by body weight (BW; ≤60 kg vs . >60 kg). The primary endpoint was timely absolute neutrophil count (ANC) recovery before the second cycle of chemotherapy.

Results

A total of 122 patients were randomized and 116 were included for efficacy analyses. The timely ANC recovery rate in the 3 mg arm was 89.8%, compared to 93.0% in the 6 mg arm (one‐sided 95% confidence interval [CI] lower limit for difference: −11.7%), meeting the prespecified non‐inferiority margin of 15%. The rate was 93.3% with PEG‐rhG‐CSF 3 mg and 96.6% with 6 mg in patients with BW ≤ 60 kg, and 86.2% and 89.3%, respectively, in those with BW > 60 kg. Although the incidence of severe neutropenia was similar across arms, the occurrence of excessively high ANC and white blood cell counts was higher in the 6 mg arm. No grade ≥3 adverse events related to PEG‐rhG‐CSF occurred.

Conclusion

Three milligrams of PEG‐rhG‐CSF per cycle provided non‐inferior neutrophil protection and attenuated neutrophil overshoot compared to 6 mg doses. This low‐dose regimen could be a new supportive care option for Chinese breast cancer patients receiving anthracycline‐based adjuvant chemotherapy.

Subjects

MeSH terms (MEDLINE)

Breast NeoplasmsPolyethylene GlycolsGranulocyte Colony-Stimulating FactorNeutropeniaRecombinant ProteinsHumansFemaleMiddle AgedAdultChemotherapy, AdjuvantNeutrophilsChinaAgedAntineoplastic Combined Chemotherapy ProtocolsLeukocyte CountDose-Response Relationship, DrugEast Asian People

Author keywords

dose‐dense chemotherapyneutropeniapegfilgrastimpegylated recombinant human granulocyte‐colony stimulating factorprimary breast cancer

Substances

Polyethylene GlycolsGranulocyte Colony-Stimulating FactorRecombinant Proteinspegylated granulocyte colony-stimulating factor, human

Authors and institutions

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

ORCID profiles: Pin Zhang

Funding

  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • National Natural Science Foundation Fund of China
  • National Outstanding Youth Science Fund Project of National Natural Science Foundation of China

Cite

APA

Yang, S., Chen, S. S., Zhang, C. G., Zhou, Y. L., Xiu, M., & Zhang, P. (2024). Low‐dose pegylated recombinant human granulocyte‐colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open‐label, randomized, non‐inferiority trial. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16151

Vancouver

Yang S, Chen SS, Zhang CG, Zhou YL, Xiu M, Zhang P. Low‐dose pegylated recombinant human granulocyte‐colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open‐label, randomized, non‐inferiority trial. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16151

BibTeX
@article{Yang2024,
  author = {Yang, Sheng and Chen, Shan-Shan and Zhang, Chang-Gong and Zhou, Ying-Lei and Xiu, Meng and Zhang, Pin},
  title = {Low‐dose pegylated recombinant human granulocyte‐colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open‐label, randomized, non‐inferiority trial},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16151}
}
Start for free →